Wednesday, 9 July 2014

Genetics Studies in Diabetes - Part 1

It is useful to consider basic terminology and then focus on the potential benefits of genetic analyses (OmniaMed)

FDA Accepts Sanofi’s New Drug Application for Basal Insulin Toujeo®

The U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL),an investigational basal insulin (Sanofi)

Validating an ontology-based algorithm to identify patients with Type 2 Diabetes Mellitus in Electronic Health Records

This DMO-based algorithm is sufficiently accurate to support a semantic approach, using the RFV, Rx and Path to define patients with T2DM from EHR data. However, the accuracy can be compromised by incomplete or incorrect data. The extent of compromise requires further study, using ontology-based and other approaches (International Journal of Medical Informatics)

No comments:

Post a Comment